Financing ·
Mirum Pharmaceuticals reported second quarter 2026 net product sales of $176.2 million and raised full-year guidance…
MIRMMirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals reported second quarter 2026 net product sales of $176.2 million and raised full-year guidance to $680–$700 million. The company issued $690 million in convertible senior notes due 2032 and settled approximately 75% ($237.2 million) of its 2029 convertible notes, holding $561.3 million in unrestricted cash as of June 30, 2026. Regulatory updates include FDA Breakthrough Therapy designation for volixibat in primary sclerosing cholangitis and a pre-NDA meeting indicating a potential Phase 3 study before an H1 2027 submission. Zilurgisertib’s PDUFA date is September 26, 2026, while brelovitug topline results are expected in Q3 and Q4 2026. Mirum Pharmaceuticals operates as a rare disease company focused on liver and genetic diseases.